Kubota Pharmaceutical Holdings: Confirmatory letter.
Kubota Pharmaceutical Holdings: Interim report - 10th period (01/01/2024 - 12/31/2024).
Kubota Pharmaceutical Holdings: Consolidated financial results for the six-month period ending June 30, 2024 (based on IFRS).
Kubota Pharmaceutical Holdings: 2Q of the fiscal year ending December 2024, financial results announcement (IFRS) (consolidated)
Kubota Pharmaceutical Holdings: Announcements of individual stocks regarding business partnership with Sojitz Kyushu Corporation.
Kubota Pharmaceutical Holdings: Announcements of individual stocks on the monthly exercise status of the 28th subscription rights (with exercise price adjustment clause).
Kubota Pharmaceutical Holdings: Announcements of individual stocks for new patent acquisition in the USA.
Kubota Pharmaceutical Holdings: Change Report (Stock Certificates Eligible for Special Provisions, etc.)
Kubota Pharmaceutical Holdings: Announcements of individual stocks: Notice of delivery of 'Kubota Glass' to Sanyo Kyushu, the partnership has started to expand sales in China.
Kubota Pharmaceutical Holdings: Decision to rationalize management by transferring research, development, and management bases from USA to Japan.
Kubota Pharmaceutical Holdings: Announcements of individual stocks on the monthly exercise status of the 28th subscription rights (with exercise price adjustment clause).
Kubota Pharmaceutical Holdings: (Correction) Partial correction of 'Japan Retinal Pigmentary Dystrophy Association submits request to PMDA for early approval of 'Emiclustat hydrochloride' a candidate for Stargardt disease treatment'.
Kubota Pharmaceutical Holdings: The Japan Macular Degeneration Association submitted a request letter to PMDA, seeking early approval for the candidate drug for Stargardt's disease treatment, Emixustat hydrochloride.
Kubota Pharmaceutical Holdings: Notice regarding the monthly exercise status of the 28th Stock Acquisition Rights (with exercise price amendment clause)
KUBOTA PHARMACEUTICAL HLDGS: Notice of obtaining a new patent in the US
KUBOTA PHARMACEUTICAL HLDGS: [Delayed] Consolidated financial results for the 3 months ended March 31, 2024 (based on IFRS)
KUBOTA PHARMACEUTICAL HLDGS: Confirmation letter
KUBOTA PHARMACEUTICAL HLDGS: Summary of financial results for the 1st quarter of the fiscal year ending 2024/12 [IFRS] (consolidated)
KUBOTA PHARMACEUTICAL HLDGS: Quarterly Report - 10th Quarter 1st Quarter (2024/01/01 - 2024/03/31)
KUBOTA PHARMACEUTICAL HLDGS: Announcement of speakers at ARVO (Vision and Ophthalmology Research Association) 2024 Annual General Meeting
No Data